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Brianna Strube, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND  58202-9037
Abstract 
Introduction
• There is variability in the pathophysiology of depression and not all 
details are known. Despite recent advances in the use of 
antidepressants, interindividual variability to treatment remains a serious 
problem. As patients continue to fail medication regimens, the likelihood 
of responding to subsequent treatment decreases to 18%. Furthermore, 
depression has one of the highest instances of mortality from suicide. 
• Pharmacogenetic testing has been developed to test a set of preselected 
psychiatric genes to provide a composite phenotype and accompanying 
interpretative report. By predicting the drug response of an individual, it 
may be possible to increase the success rate of antidepressant use and 
reduce the incidence of adverse side effects.
Research Questions
Literature Review
Applicability to Clinical Practice
Discussion
In summary this research found
• Pharmacogenomic-guided treatment has shown effectiveness and 
improved patient outcomes when compared to the current standard 
of treatment. 
• The utility of this genetic information as it pertains to clinical 
decision making, treatment effectiveness, and cost savings has 
shown benefit for patients with moderate to severe depression who 
have failed prior treatment. 
• Pharmacogenetic testing provides significant cost savings, while 
simultaneously improving adherence in a difficult to treat 
psychiatric population. Patients who had pharmacogenetic-guided 
treatment had improved outcomes in addition to decreased cost to 
the patient by having fewer clinic visits, less changes in 
prescriptions, lessened and shorter sick leave taken, and decreased 
hospital costs. 
• In adult patients with a diagnosis of major depressive disorder, 
does utilizing pharmacogenetic testing to determine 
antidepressant use result in improved patient outcomes?
• Is pharmacogenetic testing for the patient with major depressive 
disorder cost effective?
• Altar et al. (2015) found subjects who entered the study on red 
category medications showed 61.5% less improvement in 
depressive symptoms over 8–10 weeks compared with those 
prescribed yellow (t = 3.15; P = 0.002), green (t = 2.22, P = 0.02) or 
yellow ± green category medications (t = 2.97, P = 0.003).
• Hall-Flavin et al. (2013) found the pharmacogenetic guided group 
experienced greater percent improvement in depression scores 
from baseline on three depression instruments (HAMD-17, P < 
0.0001; QIDS-C16, P < 0.0001; PHQ-9, P < 0.0001) compared with 
the unguided group. Using repeated measures analysis for all 
participants who completed the 8-week study, a greater reduction 
of symptoms was observed for guided group participants compared 
with unguided group participants for HAMD-17 (P < 0.001), QIDS-
C16 (P < 0.001), and PHQ-9 (P = 0.002) (Figure 2). Significantly 
greater response rates (i.e. >50% reduction in score from baseline) 
were found in the guided group versus the unguided group at week 
8 as determined with QIDS-C16; 44.4% of participants in the 
guided group responded versus 23.7% in the unguided group. 
HAMD-17 and PHQ-9 showed nearly identical results.
• Winner et al. (2013) determined that the likelihood of response and 
remission was greater than double in the GeneSight guided group 
measured by HAMD-17 at week 10. Mean percent improvement in 
symptoms on HAMD-17 was higher for the GeneSight group over 
treatment as usual (30.8% vs 20.7%; p=0.28).
• Singh (2015) found that subjects receiving genetically guided 
prescribing had a 2.52-fold greater chance of remission (p<0.0001).
• Fagerness et al. (2014) found that individuals with assay-guided 
treatment were significantly more medication adherent (P = 0.002) 
than patients with standard treatment and demonstrated a relative 
cost savings of 9.5% in outpatient costs over a 4-month follow-up 
period, or $562 in total savings.
• As a newer topic in the medical field, efforts are needed to improve 
clinicians’ knowledge of pharmacogenetic testing in order to facilitate its 
successful integration into clinical practice. 
• Pharmacogenetic testing can aid in directing treatment towards a more 
effective approach. 
• Medicare Part B and Veterans Affairs cover pharmacogenetic testing if 
deemed medically necessary. 
• Pharmacogenetic testing is a relatively new concept, but has been proven 
to have advantages over the current treatment of MDD. It offers providers 
an effective resource to provide improved outcomes for patients with MDD 
requiring pharmacotherapy. 
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• Major depressive disorder (MDD) is one of the most prevalent 
psychiatric disorders in the United States and is a large cause of 
disability. Antidepressants take weeks/months to become effective which 
can lead to noncompliance. Treatment has a high failure rate which 
increases medical costs and leads to decreased patient outcomes.
• Pharmacogenetic testing is the practice of analyzing genetic differences 
to predict a patient’s response to medications to improve efficacy and 
decrease adverse side effects. The purpose of this study was to 
investigate if pharmacogenetic-guided treatment, specifically in the use 
of antidepressants in MDD, has resulted in improved patient outcomes. 
Additionally, the cost effectiveness was also analyzed. 
• The review of literature was conducted by systematically searching the 
online databases PubMed and PsycINFO, and explored studies that 
compared the current standard of care to pharmacogenetic-guided 
treatment in adult patients with MDD aged 18-75.
• The results indicated improved compliance and prognosis for patients 
with MDD using pharmacogenetic-guided treatment versus the current 
standard of care. Studies also showed cost effectiveness of 
pharmacogenetic-guided treatment by decreasing medical costs by 
having fewer clinic visits, less changes in prescriptions, less sick leave 
taken, and decreased hospital costs. 
Major depressive disorder is associated with a high prevalence of 
therapeutic failure, adverse side effects from medications, and a high 
recurrence rate. Response to antidepressants take an extended length of 
time which leads to noncompliance and increased medical costs due to 
additional follow-up visits and prescription costs. 
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Figure 1. 
Figure 2. Repeated measures analysis by depression scale. (Hall-Flavin, 2013)
Figure 1. GeneSight integrative methodology. (Winner, 2013)
